🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As we await FUSION PHARMA $FUSN to reveal its interim data from the Phase 2 TATCIST Clinical Trial evaluating FPI-2265 at the 2024 AACR in April, RBC did an amazing job in providing RadioPharma landscape (below image from the recent report titled: Radiopharma on the Rise)

BREAKING: Our co-creation exits now totaling US$3.5B in <12 months: $FUSN to be acquired by $AZN for $2.4B Congrats to John Valliant & Fusion Pharmaceuticals team! Damian Lamb was the inaugural Chairman of the Board, from company creation through IPO. ir.fusionpharma.com/2024-03-19-Fus…

Good news keeps on flowing here at Genesys: Flosonics secures US$20M Series C to accelerate growth. Led by New Leaf Ventures , with participation from previous investors @ArboretumVC, Genesys Capital & iGan Partners Congrats to Joe Eibl & FloPatch | Flosonics Medical team! flosonicsmedical.com/flosonics-medi…

No better guest speaker than Genesys' Jamie Stiff for a lecture on "EXITS" - especially as Genesys had US$3.5 Billion in exits since last fall Kudos to CVCA & Ivey Business School to put together such a good event - CPCIS Program (Canadian Private Capital Investment School)

Origin Story of Fusion Pharmaceuticals $FUSN Last week Genesys portfolio company Fusion Pharmaceuticals announced its acquisition by AstraZeneca! Check out our contributions to this Canadian success story below

Fusion Pharma reveals early Ph2 data from FPI-2265 at #AACR2024 "PSA50 of 50% Exceeds Expectations; Uptake Response and Post-Pluvicto Activity Encouraging; Safety in Line With Previous Data" Andy T. Hsieh, Ph.D. at William Blair Link to the poster - qrcodes.pro/y32gAO

Congratulations to Genesys Partner and CFO Jennifer Williams on being appointed to the Board of the CVCA ! Proud to have Genesys Capital represented!

This week AstraZeneca completed the acquisition of Genesys portfolio company Fusion Pharmaceuticals for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals. prnewswire.com/news-releases/…

Congrats to our very own Damian Lamb for being recognized with a 2024 Alumnus Award from McMaster University! Damian has been committed to supporting the commercialization of McMaster's world-class research for many years #FusionPharma #CPDC alumni.mcmaster.ca/s/1439/22/alum…

TWO Genesys co-creations make the list of Fierce's "Top 10 smartest deals in biopharma" - Inversago Pharma & Fusion Pharmaceuticals! A tribute to the value of the Genesys investment thesis #madeinCanada fiercebiotech.com/biotech/smarte…

Big News for Profound Medical! The CMS has proposed Category 1 CPT codes for TULSA, putting its reimbursement in the same ballpark as standard of care radical prostatectomy, but with better safety outcomes. Raymond James rates as a Strong Buy. globenewswire.com/news-release/2…

Last month, Fusion Pharmaceuticals exited to AstraZeneca for $2.4 Billion USD - a Genesys co-creation that has become a Canadian anchor company and global hub of radiopharma excellence. Check out the origin story below. linkedin.com/feed/update/ur…

With Genesys’ funding, Feldan aims to develop a first-in-class non-invasive intralesional treatment for basal cell carcinoma. We are very excited to be part of Feldan’s “drug delivery platform” mission and it’s an excellent addition to our newest Fund. newswire.ca/news-releases/…

Genesys is closing out a fantastic week at this year’s Morgan Stanley Healthcare Conference in NYC. A highlight for us was hearing Novo Nordisk's excitement about Monlunabant, acquired from Inversago Pharma last year, and its potential to change the landscape of metabolic disease!

Novo announces Monlunabant (Inversago’s INV-202) Phase 2a data in obesity, with significant weight loss after 16 weeks of treatment (7.1 kg with a once daily 10 mg dose). Based on the results, Novo expects to initiate a larger Phase 2b trial in 2025 novonordisk.com/content/nncorp…

What an achievement for Profound Medical! “TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement" - which speaks to the value of the TULSA system. Congrats to the Profound team! globenewswire.com/news-release/2…

Toronto host Taylor’s ERAS tour, we're posting our ERAS poster REPUTATION ERA reflects top-decile DPI w/ exits of Fusion Pharma & Inversago (US$3.5B), & we’re still not done yet – stay tuned for Flosonics/Questat/Veralox Embarking on our EVERMORE ERA - get your tix today🍁

Congrats to Profound Medical on joining forces with Siemens Healthineers under a co-sale and co-marketing agreement! Will be exciting to watch how this partnership + attractive reimbursement drives sales in 2025 #TULSA #prostatecancer #BPH globenewswire.com/news-release/2…

Team Genesys is heading for the 25th time to the #JPM25. The weather forecast looks better than the last year's & we hope that this lifts sentiments across the life sci sector Also, Genesys originated company Profound Medical will be presenting for the 1st time at JPM this year.

Big News from Genesys Capital! We’re thrilled to unveil our brand new logo and revamped website! 🎉 Check out the new site here: genesyscapital.com